BridgeBio: Positive Phase 1 Data and Phase 2/3 Trial Design for Kidney Stones

 – BBP-711 led to near complete inhibition of glycolate oxidase throughout the dosing period and greater than 10-fold increases in plasma glycolate, suggesting it has the potential to be both a best-in-class therapy and the first oral therapy for PH1 and recurrent kidney stone formers

– Based on the tolerability and potency of the oral therapy, BridgeBio has met with regulators and intends to initiate a Phase 2/3 pivotal study by the end of 2022

– At the end of 2022, BridgeBio also intends to launch a Phase 2 study of BBP-711 in adult recurrent kidney stone formers, which affects an estimated 1.5 million individuals in the United States and European Union

https://finance.yahoo.com/news/bridgebio-pharma-announces-positive-phase-113000372.html